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Abstract 
Glucocorticoid (GC) action depends on GC plasma concentration, cellular GC receptor 
expression and the pre-receptor hormone metabolism catalyzed by 11β-hydroxysteroid 
dehydrogenase (11β-HSD). 11β-HSD exists in two isoforms; 11β-HSD1 converts inactive 
cortisone to cortisol and 11β-HSD2 converts cortisol to cortisone. Increasing evidence in 
humans and experimental animals suggests that altered tissue cortisol metabolism may 
predispose to diabetes mellitus (DM). Once DM is established, hyperglycemia and 
hyperlipidemia may further maintain the abnormal metabolism of cortisol. To gain further 
insight in this regard, healthy cats were infused for 10 days with lipids (n=6) or saline (n=5). 
At the end of the infusion period, tissue samples from adipose tissue (visceral, subcutaneous), 
liver and muscle were collected to determine mRNA expression of 11β-HSD1, 11β-HSD2 
and GC receptor by real-time RT-PCR; blood samples were collected to determine plasma 
cortisol and leptin concentrations. Lipid infusion resulted in higher 11β-HSD1 expression and 
lower GC receptor expression in visceral and subcutaneous adipose tissues, and lower 11β-
HSD2 expression in visceral adipose tissue and liver. Plasma cortisol did not differ. Leptin 
and body weight increased in lipid-infused cats. In spite of comparable circulating cortisol 
levels, up-regulation of 11β-HSD1 and down-regulation of 11β-HSD2 expression may result 
in increased tissue cortisol concentrations in fat depots of hyperlipidemic cats. Down-
regulation of GC receptor may represent a self-protective mechanism against increased tissue 
cortisol levels. In conclusion, hyperlipidemia has a profound effect on the 11β-HSD 
expression and supports the connection between high lipid levels and tissue cortisol 
metabolism. 
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1. Introduction 
Type-2 diabetes mellitus (DM) is characterized by inadequate insulin secretion and impaired 
insulin action (insulin resistance). Circulating cortisol levels are often normal in humans with 
DM or impaired glucose tolerance [1,2], but there is considerable evidence that 
glucocorticoids (GC) decrease insulin sensitivity [3-5]. Circulating GC concentrations alone 
may not reflect the concentration of cortisol in the target tissues of insulin (e.g. liver, adipose 
tissue and muscle). In fact, the tissue cortisol concentration is mainly controlled by two 
enzymes: 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) and 11β-hydroxysteroid 
dehydrogenase 2 (11β-HSD). 11β-HSD1 is NADP(H)-dependent and acts predominately as 
an oxo-reductase in vivo, generating the active cortisol from cortisone [6]. It potentiates the 
actions of GC in tissues and is widely distributed in the body with highest expression in liver 
and adipose tissue [7]. 11β-HSD2 utilizes NAD to inactivate cortisol to cortisone. It serves to 
protect the mineralocorticoid receptor (MR) from cortisol excess and is expressed in MR-rich 
tissues, such as kidney, colon and salivary glands [8,9]. A pathogenetic role of 11β-HSD1 in 
insulin resistance is supported by several animal models. Mice overexpressing 11β-HSD1 
developed obesity, DM and hyperlipidemia [10]. 11β-HSD1 knockout mice, however, 
showed resistance against the development of obesity and glucose tolerance and an increase in 
hepatic insulin sensitivity [11,12]. In addition, selective inhibition of 11β-HSD1 in mice lead 
to increased glucose tolerance and insulin sensitivity and decreased body weight, cholesterol 
and triglycerides [13,14].  
Type-2 DM is closely related to obesity [15,16]. In both conditions, circulating triglycerides 
and free fatty acids (FFA) are frequently increased. Elevated FFAs induce peripheral and 
hepatic insulin resistance [17,18]. Whether FFA-induced insulin resistance in humans is 
mediated by local elevated cortisol levels due to increased 11β-HSD1 activity was recently 
examined in two experiments. Acute hyperlipidemia, induced by 3-6 hours of lipid infusion, 
did not change hepatic 11β-HSD1 activity, but caused an increase in 11β-HSD1 activity in 
subcutaneous adipose tissue [19,20]. The effect of prolonged lipid infusion over several days 
on 11β-HSD1 activity or expression has not been studied so far. Feline DM is an interesting 
model for human type-2 DM because it shows several pathophysiological similarities, 
including obesity-induced insulin resistance, impaired β-cell function, decreased number of β-
cells and pancreatic amyloid deposition [21-23]. The aim of the present study was therefore to 
test whether prolonged lipid infusion in cats, with clamping of the triglyceride plasma 
concentration at the level found in untreated diabetic cats, has an influence on tissue cortisol 
metabolism; specifically we wanted to study whether lipid infusion affects 11β-HSD1, 11β-
HSD2 and GC receptor expression in insulin sensitive tissues. Additionally, the influence of 
hyperlipidemia on plasma cortisol and leptin concentrations was evaluated.  
 
2. Material and methods 
2.1. Animals and infusions 
Eleven healthy neutered male domestic short hair cats (Charles River, L’Arbresle, France) 15-
18 months old (median 16 months) and weighing 3.4-4.8 kg (median 3.9 kg) were maintained 
at the animal care facility of the Clinic for Small Animal Internal Medicine, Vetsuisse 
Faculty, University of Zurich, Switzerland. Animal studies were approved by the Cantonal 
Veterinary Office of Zurich (permission nr. 51/2007). Cats were determined to be healthy on 
the basis of physical examination and clinical laboratory data; cats were at optimal body 
weight, based upon body condition (i.e., score 5/9 in all cats; Body Condition Score chart) 
[24]. They were fed twice/day with a commercial diet (PVD Feline DM Diet, Nestlé-Purina, 
St. Louis, MO, USA) given at a maintenance dose, and had free access to water.   
For the experiment cats were randomly divided into two groups, housed in single cages and 
infused over 10 days through a jugular catheter. Group I (n=6) received a commercial lipid 
infusion (Lipovenoes 10%, Fressenius-Kabi, Bad Homburg, Germany). The lipid composition 
is provided in Table 1. Blood triglyceride levels were measured two or three times daily to 
target levels at 3-7 mmol/l. Group II (n=5) served as control and was infused with saline at a 
maintenance rate (2 ml/kg/h). 
 
2.2. Biochemical measurements 
Plasma glucose was measured by a colorimetic hexokinase/glucose-6-phosphate 
dehydrogenase method, and triglycerides were measured by a colorimetric assay using 
glycerophosphate oxidase coupled to phenol and 4-aminophenazone (Roche, Vienna, 
Austria). Serum NEFAs were measured using the NEFA-C kit (Wako, Richmond, PA, USA).  
A cross-reacting porcine insulin radioimmunoassay (Linco, St. Charles, MO, USA) was used 
to determine insulin concentrations [25]. Serum cortisol was measured by a 
chemiluminescence immunoassay (ADVIA Centaur® System, Bayer (Schweiz) AG, Zurich, 
Switzerland) and leptin levels were determined by a radioimmunoassay (Linco, St. Charles, 
MO, USA) [26]. 
 
2.3. Assessment of insulin sensitivity and tissue sample collection 
During the 10-day infusion, overnight fasting blood samples were collected through the 
jugular catheter daily at 8:00 h to measure glucose and insulin. An intravenous glucose 
tolerance test (IVGTT) was performed under anesthesia in fasted cats 1 hour after the 10-day 
infusion. A glucose bolus of 1 g/kg was administered via the jugular catheter. Glucose and 
insulin were measured before the bolus and then at 5, 10, 15, 30, 45, 60, 90 and 120 minutes 
thereafter. The whole body insulin sensitivity index was calculated as described [27]. After 
IVGTT, cats were euthanized and tissue samples were collected within 30 minutes. Visceral 
(mesenteric) fat was collected adjacent to the jejunum, subcutaneous fat from the inguinal 
area, liver from the right caudal liver lobe and skeletal muscle from the vastus lateralis. The 
samples were immediately frozen into liquid nitrogen and stored at -80 ºC until further use.  
 2.4. RNA-isolation and cDNA synthesis 
Total RNA from about 30 mg tissue was isolated using the RNeasy Mini kit (Qiagen, Basel, 
Switzerland). RNA was stored at -80 ºC until reverse-transcription (< 3 months). Negative 
controls containing only phosphate buffered saline (PBS 1×) were also co-extracted to 
monitor potential cross-contamination during the RNA isolation step. The purity and 
concentration of the extracted RNA was measured by optical density with a 
spectrophotometer (Nanodrop ND-100, Witec AG, Littau, Switzerland). A fixed amount (1 
μg) of RNA was reverse-transcribed into cDNA. Genomic DNA was digested and RNA 
reverse-transcribed by the QuantiTect Reverse Transcription Kit (Qiagen). The cDNA was 
stored at -20 ºC (< 3 months).  
 
2.5. Establishing and validation of the TaqMan® real-time PCR assays 
Probe and primer sequences for the TaqMan® fluorogenic real-time PCR assays were 
designed using PrimerExpressTM software (Version 2.0., Applied Biosystems, Rotkreuz, 
Switzerland) based on the feline 11β-HSD1 (AY496705), 11β-HSD2 (AY496706), GC 
receptor (DQ501388) and Leptin (AB041360) sequences deposited in the GenBank. For 
GAPDH a previously established system was used [28]. The primer and probe sequences are 
listed in Table 2.  
The specificity of the PCR primers was assessed by amplifying target DNA using the 
respective primer sets without probe. The PCR products of 11β-HSD1, 11β-HSD2, GC 
receptor and leptin were analyzed by gel electrophoresis, purified and sequenced as described 
elsewhere [29]. All four PCR systems produced a single band at the expected length. 
Sequencing revealed identical nucleotide sequences compared to those for cats available in 
the public sequence database. 
For all assays DNA was amplified and quantified in an ABI Prism 7700 sequence detection 
system (Applied Biosystems). Reactions were performed in triplicates for every feline cDNA 
sample. PCR reactions were prepared with 12.5 μl qPCRTM Mastermix (Eurogentec, Seraing, 
Belgium), a final concentration of 900 nM primers (Microsynth, Balgach, Switzerland), 250 
nM of fluorogenic probe (Microsynth and Eurogentec) and 5 μl of template cDNA in a 25 μl 
total reaction volume. After an initial step of 2 min at 50 ºC, a denaturation of 10 min at 95 ºC 
was followed by 45 cycles of 95 ºC for 15 sec and 60 ºC for 1 min. 
The amplification efficiencies of all five assays were determined in duplicates using serial 10-
fold dilutions of cDNA. The efficiencies of the assays for different targets were compared to 
each other by assessing the slopes (s) of the curves (threshold cycle versus dilution) and 
considered comparable if the difference of the slope (Δs) was smaller than 0.1. Amplification 
efficiencies were calculated as 101/-s-1 [29]. The slopes of the dilution versus threshold cycle 
curves were -3.45, -3.30, -3.31, -3.36 and 3.48 for 11β-HSD1, 11β-HSD2, GC receptor, leptin 
and GAPDH, respectively. This translated into amplification efficiencies of 95%, 99.5%, 
99.5%, 98% and 94% for 11β-HSD1, 11β-HSD2, GC receptor, leptin and GAPDH DNA 
PCR, respectively. 
Within- and between-run precision of the assays were assessed by measuring different cDNA 
dilutions repetitively. Three cDNA samples were evaluated in 10 replicates (within-run 
precision) and in five separate experiments (between-run precision). For all measurements, 
mean value, standard deviation, and coefficients of variation (CV) were calculated for the 
threshold cycle (CT) values (CVCT). The CVCT of the within-run precision experiments were 
0.2-0.4%, 0.3-0.7%, 0.4-0.6%, 0.2-0.4%, and 0.3-0.5% for 11β-HSD1, 11β-HSD2, GC 
receptor, leptin and GAPDH, respectively. The CVCT of the between-run experiments were 
0.3-0.7%, 0.5-1.1%, 0.5-1.2%, 0.4-1.3% and 0.6-0.8%, respectively. 
 
2.6. Relative quantitation of mRNA expression 
The relative quantification of expression of 11β-HSD1, 11β-HSD2, GC receptor and leptin 
was determined by real-time PCR using the comparative CT method [29]. In order to 
minimize variations all sequences of interest were amplified in parallel from of the same 
cDNA aliquot on the same plate.  
 
2.7. Statistical analysis 
Results were analyzed by non-parametric statistical methods (GraphPad Prism 4, San Diego, 
California, USA). Data are expressed as median and range. Body weight differences before 
and after infusion were compared using the Wilcoxon matched pairs test. Hormone and PCR 
results of lipid- and saline-infused cats were compared using the Mann-Whitney test. 
Differences were considered significant at values of p < 0.05.  
 
3. Results 
3.1. Clinical course during the infusion experiment 
The ten-day hyperlipidemic clamp was well tolerated in cats. The detailed clinical course 
(food intake, physical examination, electrolyte monitoring, blood glucose concentrations, 
plasma triacylglycerol concentrations) has been described by Zini et al. 2009. After infusion, 
body weight decreased slightly in saline-infused cats (average difference: -4.3%) and 
increased significantly in lipid-infused cats (average difference: +10.7%, p< 0.05) (Table 3).  
 
3.2. Serum cortisol, leptin and NEFA concentrations at the end of the infusion period  
(Table 3) 
Cortisol levels were not significantly different between lipid- or saline-infused cats (lipids: 
median: 63.5 nmol/L, range: 8.3-124.2; saline: median: 149.0 nmol/L, range: 38.6-160.0).  
Lipid-infused cats had significantly higher leptin concentrations than saline-infused cats 
(lipids: median: 4.8 μg/L, range: 3.3-8.3; saline: median: 2.1 μg/L, range: 1.9-2.6; p<0.005).  
The NEFA concentration was significantly higher in lipid-infused cats than in saline-infused 
cats (p<0.05). The NEFA area under the curve during the infusion period was significantly 
higher in lipid-infused cats (median: 0.76 mmol/L, range: 0.5-1.28) than in saline-infused 
(median: 0.49 mmol/L, range: 0.28-0.69, p < 0.05) cats. 
 
3.3. 11β-HSD1, 11β-HSD2, GC receptor and leptin expression in different tissues 
3.3.1. Subcutaneous adipose tissue (Figure 1) 
Gene expression for 11β-HSD1 was significantly higher and that for GC receptor 
significantly lower in lipid-infused than in saline-infused cats (p<0.005, p<0.005 ). Levels of 
mRNA encoding 11β-HSD2 and leptin did not differ between the groups (not shown). 
 
3.3.2. Visceral adipose tissue (Figure 2) 
Gene expression for 11β-HSD1 was significantly higher, that for 11β-HSD2 and GC receptor 
significantly lower in lipid-infused than in saline-infused cats (p<0.005, p<0.005, p<0.005). 
Levels of mRNA encoding leptin did not differ between the groups (not shown). 
 
3.3.3. Liver (Figure 3) 
Gene expression for 11β-HSD2 was significantly lower in lipid-infused than in saline-infused 
cats (p<0.005). Levels of mRNA encoding 11β-HSD1 and GC receptor did not differ between 
the groups (not shown). Leptin mRNA was not detectable in liver. 
 
3.3.4. Skeletal muscle 
There was no significant difference in gene expression for 11β-HSD1, 11β-HSD2, GC 
receptor or leptin between the groups (not shown).  
 
3.4. Insulin sensitivity (Figure 4) 
At day 10, the calculated whole body insulin sensitivity index of lipid- and saline-infused cats 
was not different.  
 
 
4. Discussion 
This is the first study evaluating the effects of prolonged lipid infusion on 11β-HSD 
expression in different tissues. The results show that 10-day hyperlipidemia leads to increased 
11β-HSD1 expression in subcutaneous and visceral adipose tissue and decreased 11β-HSD2 
expression in visceral adipose tissue and liver. 11β-HSD1 generates cortisol from cortisone, 
whereas 11β-HSD2 inactivates cortisol to cortisone [6,7]. Up-regulation of 11β-HSD1 and 
down-regulation of 11β-HSD2 in adipose tissue therefore would be expected to lead to an 
increased tissue cortisol level. These results are in accordance with two studies in humans. In 
the first study, lipid infusion for 6 hours did not change hepatic and whole body 11β-HSD1 
activity [19]. In the second study, however, lipid infusion for 3.5 hours induced a significant 
increase in 11β-HSD1 activity in the subcutaneous adipose tissue [20].  
The whole body insulin sensitivity of cats after 10 days of lipid infusion was not significantly 
different to that of the control cats. Importantly, one has to consider, that with the IVGTT we 
only measured the global insulin sensitivity of the body and not the individual insulin 
sensitivity of the adipose tissue or other organs. Because the main effects of hyperlipidemia 
seem to occur in the adipose tissue, it seems plausible to assume that, if adipose tissue insulin 
sensitivity had been measured separately, a difference in the insulin sensitivity between lipid-
infused and saline-infused cats would have been detectable seems justifiable. Different from 
the result in cats, former studies in humans and rodents consistently showed an impairment of 
whole body insulin sensitivity following lipid infusion [30-35]. Hence, it may be argued that 
the effect of hyperlipidemia on insulin sensitivity differs between cats and humans and 
rodents.  It is, however, important to understand that, even though previously used emulsions 
were similar to ours, infusion times have been much shorter. Further, infusions were typically 
given at constant and relatively high rates. Experiments in humans and rodents have not been 
conducted to verify whether insulin sensitivity is still impaired after 10 days of lipid infusion 
in the diabetic range. It is therefore possible that lipid-induced insulin resistance, observed 
during short-term lipid infusion in humans and rodents, may no longer be present after 10-day 
infusion, due to some as yet unknown compensatory mechanisms.  
In addition, to increased 11β-HSD1 and decreased 11β-HSD2 expression in adipose tissue, 
10-day hyperlipidemia led to significantly decreased GC receptor expression. GC receptor 
expression has been shown to be inversely correlated with 11β-HSD1 expression, suggesting 
that compensatory autoregulation of this receptor might modulate the local effects of 
increased intra-adipose cortisol concentrations [36]. The importance of the GC receptor in the 
pathogenesis of insulin resistance, obesity and HC is emphasized by several rodent studies: in 
diabetic db/db mice and obese Zucker rats increased hepatic GC receptor mRNA expression 
caused hyperglycemia and insulin resistance. Conversely, selective inactivation of GC 
receptor improved insulin resistance and obesity in diabetic animals and patients with 
hypercortisolism [37-40]. Therefore, one could argue that the decreased GC receptor 
expression seen in this study exhibits a self protecting mechanism of the tissue against the 
increased tissue cortisol. 
Interestingly, the levels of GC receptor mRNA in cats did not differ between subcutaneous 
and visceral adipose tissue. This was also confirmed by examination of its expression in 
visceral and subcutaneous adipose tissue of 21 healthy cats [Sieber and Zini, unpublished 
data]. This finding differs from results from rodents and humans, where GC receptor mRNA 
levels were threefold higher in visceral compared to subcutaneous adipose tissue [10,41]. 
Enhanced GC receptor expression in visceral fat is discussed as one reason for an exaggerated 
accumulation of fat in this depot (visceral obesity) [10]. The different GC receptor mRNA 
expression in adipose tissue of cats could therefore fit to the finding that abdominal fat 
deposits in obese cats are equally distributed subcutaneously and intra-abdominally [42]. 
Concerning body fat distribution, however, one has to consider the sexual status of an 
individual, as gonadal steroids are known to mediate body fat deposition [43,44]. In this study 
and in the study of Hoenig et al. all cats were neutered; this could influence body fat 
distribution and possibly GC receptor expression. 
Although considerable changes in 11β-HSD1, 11β-HSD2 and GC receptor expression were 
seen in lipid-infused cats, their serum cortisol concentrations at the end of the study did not 
differ from that of saline-infused cats. This suggests that the prolonged hyperlipidemia indeed 
influences the tissue cortisol metabolism but that the general cortisol secretion may not be 
influenced.  
Serum leptin concentrations were significantly increased in lipid-infused cats compared to 
control cats. This is in accordance with results from rats, in which high-fat diets led to 
significantly elevated serum leptin concentrations and significant changes in body mass 
[38,45]. Feeding a high-fat diet to cats induced a moderate but not significant elevation in 
leptin levels [26]. Leptin mRNA expression in adipose tissue did not correlate with serum 
leptin concentrations after 10 days of lipid infusion. Similarly, in cats fed ad libitum, tissue 
leptin mRNA expression did not change although blood leptin concentrations tended to 
increase with body weight gain [46]. This indicates that adipose tissue mRNA expression may 
not be indicative of plasma leptin concentrations in cats.  
The results of this study point towards a possible connection between hyperlipidemia and 
tissue cortisol metabolism.  Triglycerides and FFAs are frequently increased in obesity and 
type-2 DM and an induction of peripheral and hepatic insulin resistance by FFAs has been 
reported in humans [17,18]. This study highlights one possible mechanism by which FFAs 
could influence tissue insulin sensitivity and the potential role of 11β-HSD1 in the 
pathophysiology of type-2 DM and obesity. Further studies in this field should substantiate 
the findings of this study and possibly focus on the influence of FFAs on other important 
enzymes that metabolize cortisol in tissues. Additionally, examination of 11β-HSD1 
expression in adipose tissue and liver of obese cats, obese and insulin resistant cats and cats 
with DM could be of major interest and could lead to insights into the role 11β-HSD1 and 
tissue cortisol metabolism in insulin resistance and DM in cats.   
A potential limitation of this study is the body weight gain during the experiment of the lipid-
infused cats. In humans, obesity is associated with an increased 11β-HSD1 activity in the 
abdominal subcutaneous and visceral adipose tissue [47,48]. Still it is unclear, if obesity is 
first and causes the increased 11β-HSD1 activity or if the increased 11β-HSD1 activity 
develops primarily and leads to obesity. That the increased body weight (and likely increased 
fat mass) had influenced the 11β-HSD1 expression in our study can’t be completely excluded. 
Future studies should address this issue by examining 11β-HSD1 expression during and after 
hyperlipidemia in animals with stable body weight.  
In conclusion, a 10-day course of hyperlipidemia had a profound influence on 11β-HSD1, 
11β-HSD2 and GC receptor expression in the subcutaneous and visceral adipose tissue of 
cats. Therefore, an association between hyperlipidemia and the tissue cortisol metabolism 
seems possible. 
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Figure legends 
Figure 1: 
11β-HSD1 and GC receptor expression in subcutaneous adipose tissue 
Relative 11β-HSD1 (a) and glucocorticoid receptor (b) mRNA load normalized to GAPDH in 
subcutaneous adipose tissue in lipid-infused and saline-infused cats. Individual and median 
values are shown. 
         
Figure 2: 
11β-HSD1, 11β-HSD2 and GC receptor expression in visceral adipose tissue  
Relative 11β-HSD1 (a), 11β-HSD2 (b) and GC receptor (c) mRNA load normalized to 
GAPDH in visceral adipose tissue in lipid-infused and saline-infused cats. Individual and 
median values are shown. 
                               
Figure 3: 
11β-HSD2 expression in liver 
Relative 11β-HSD2 mRNA load normalized to GAPDH in the liver in lipid-infused and 
saline-infused cats. Individual and median values are shown. 
  
Figure 4: 
Whole body insulin sensitivity  
Whole body insulin sensitivity in lipid-infused and saline-infused cats. Individual and median 
values are shown. 
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Table 1 
Fatty acid composition of Lipovenoes 10% (Fresenius-Kabi)  
 
Fatty acid Percentage (%) 
Linoleic acid  54  
Linolenic acid  8  
Oleic acid  26  
Palmitic acid  9  
Stearic acid  3  
 
Table 2 
Feline-specific primers and probes for quantitative mRNA analysis 
Gene Sense (5′-3′) Antisense (5′-3′) Probe (5′-3′) Product size (bp) 
11β-HSD1 CATTGTTGTCGTGTCCTCGAA CCCATCCAGGGCAAACTTG CTGGGAAAATGGCTAGTCCACTTATTGCGa 85 
11β-HSD1 CAGCAGGAGACATGCCATAC AGCTGAATGTGTCCATGAGC CTATGGGTCCTCCAAAGCGGCCa 84 
GC 
receptor 
TCTGTTCATGGCGTGAGTACCT GAAAATAGGCTTCTGATCCTGTTGTT TACCACTATGACATGAATACAGCATCCCTTTCGa 96 
Leptin AGACGATTGTCACCAGGATCAA GTCAAGACCAGCGACTCTCTGTT ACATTTCACACACGCAGTCTGTCTCCTCCa 77 
GAPDH GCCGTGGAATTTGCCGT GCCATCAATGACCCCTTCAT CTCAACTACATGGTCTACATGTTCCAGTATGATTCCAa 82 
a 5’-end labelled with the reporter dye FAM; 3’-end labelled with quencher dye TAMRA
Table 3 
 
Body weights, serum cortisol, leptin and non-esterified fatty acids (NEFA) concentrations of 
cats (median and ranges are reported) 
 Lipid-infused cats
(n=6) 
Saline-infused cats 
(n=5) 
Body weight at start of experiment (kg) 3.8 (3.4-4.8) 4.2 (3.8-4.7) 
Body weight at end of experiment (kg) 4.2 (3.8-5.3)∗ 3.9 (3.7-4.5) 
Serum cortisol concentration (nmol/L) 
at end of experiment 
64 (8-124) 149 (39-160) 
Serum leptin concentration (ug/L) 
at end of experiment 
4.8 (3.3-8.3)# 2.1 (1.9-2.6) 
NEFA concentration (mmol/L) 
at end of experiment 
0.5 (0.26-1.8)# 0.14 (0.01-0.53) 
∗ significantly higher than at the start of the experiment 
# significantly higher than levels in saline-infused cats 
 
 
 
 
